The Patent Finder

Compositions and Methods for Inhibition of the Jak Pathway

Rigel Pharmaceuticals, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 4 of these applications claim priority to application 61/368,570, filed Jul 28, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US RE47,396Compositions and Methods for Inhibition of the Jak Pathway
In force
 · Low confidence
Rigel Pharmaceuticals, Inc.In force
Low confidence
US 8,343,954Compositions and Methods for Inhibition of the Jak Pathway
In force
 · High confidence
Rigel Pharmaceuticals, Inc.In force
High confidence
US 10,479,783Compositions and Methods for Inhibition of the Jak Pathway
In force
 · Medium confidence
Rigel Pharmaceuticals, Inc.In force
Medium confidence
US 11,174,251Compositions and Methods for Inhibition of the Jak Pathway
In force
 · Medium confidence
Rigel Pharmaceuticals, Inc.In force
Medium confidence
US 9,067,925Compositions and Methods for Inhibition of the Jak Pathway
Surrendered on reissue May 21, 2019
Low confidence
Rigel Pharmaceuticals, Inc.Surrendered on reissue May 21, 2019
Low confidence
US 9,611,260Compositions and Methods for Inhibition of the Jak Pathway
Lapsed Apr 4, 2025 on the fee record
Medium confidence
Rigel Pharmaceuticals, Inc.Lapsed Apr 4, 2025 on the fee record
Medium confidence
US 9,920,041Compositions and Methods for Inhibition of the Jak Pathway
Lapsed Mar 20, 2026 on the fee record
Medium confidence
Rigel Pharmaceuticals, Inc.Lapsed Mar 20, 2026 on the fee record
Medium confidence
Application 17/494,370Compositions and Methods for Inhibition of the Jak Pathway
Abandoned
Abandoned Mar 7, 2025
Rigel Pharmaceuticals, Inc.AbandonedAbandoned Mar 7, 2025
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Rigel Pharmaceuticals, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited